Incyte logo

Incyte

INCY | NASDAQ
Chart Builder DCF Calculator
$120.27
-$0.70 (-0.58%)
At close: Nov 16, 2026, 4:00 PM ET
$116.74
-$3.53 (-2.93%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.58%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
45.4
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #381/1021 (Top 37%)

Key Statistics

Market Data

Market Cap $24.51B
1D Range
119.79 122.94
52W Range
90.30 129.93

Valuation (TTM)

PE 63.97
PB 4.34
EV/EBITDA 23.71

Valuation (NTM)

Forward PE 38.16
Forward PEG -1.07
Price Target $142.00
Loading financial charts...

Profile

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for ...

Sector Healthcare
Industry Biotechnology
Employees 2,844
IPO Date Nov 4, 1993
Fiscal Year January - December

Latest News

Incyte says EU approves oral treatment for chronic skin disease

8 hours ago · reuters.com

Incyte says EU approves oral treatment for chronic skin disease
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

8 hours ago · businesswire.com

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030

5 days ago · marketbeat.com

Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

6 days ago · seekingalpha.com

Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute

11 days ago · businesswire.com

2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday

18 days ago · benzinga.com

Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap

18 days ago · seekingalpha.com

Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

18 days ago · zacks.com

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised
Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript

18 days ago · seekingalpha.com

Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript
What Incyte (INCY) Said on Its Q3 Earnings Call

18 days ago · marketbeat.com

What Incyte (INCY) Said on Its Q3 Earnings Call

Earnings

Latest Earnings
Oct 29, 2026
EPS
-$3.6
Beat +8.40%
REV
$1.56B
Beat +6.31%
Next Earnings
Feb 9, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
19
Consensus
Hold
Price Target
$142.00
Upside
+18.07%
Buy (9)
Hold (10)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.